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Purpose: This is a report of the surgical treatment and prognosis of retroperitoneal lip-
osarcoma (RPLS) in Koreans.
Materials and Methods: Nineteen patients treated for RPLS between July 1, 1984, and 
March 31, 2009, were included. Patient demographics, histopathologic subtypes, sur-
vival rate, disease recurrence rate and interval, and adjuvant therapy were reviewed 
and analyzed.
Results: Of the 19 patients diagnosed with RPLS, 26.3% presented with well-differ-
entiated RPLS, 10.5% with dedifferentiated RPLS, 15.8% with myxoid/round cell type, 
and 47.4% with mixed-type liposarcoma. The mean follow-up period was 66.8 months 
(range, 6 to 165 months). Primary RPLS was treated in 17 patients. Nine patients 
(52.9%) had recurrent disease, and recurrence developed at a mean of 47.7 months after 
primary or repeated surgical treatment. The overall survival rate was 84.2% during 
a mean follow-up of 66.8 months. The 3- and 5-year survival rates were 86.9%, and the 
10-year survival rate was 69.5%. The recurrence interval was significantly shorter in 
recurrent RPLS cases (p=0.023). The mean growth rate of locally recurrent tumors was 
0.34 cm per month.
Conclusions: The survival rates reported here were higher than in previous studies. 
Locally recurrent tumors presented with a low growth rate, which may have con-
tributed to the relatively high survival rate. A high prevalence of mixed-type RPLS was 
also noted, and its cause and prognosis require further research. 
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INTRODUCTION 
Retroperitoneal soft-tissue sarcoma is a rare disease that 
accounts for 10 to 15% of all soft-tissue sarcomas and 33% 
of all malignant retroperitoneal tumors. Among these, lip-
osarcoma (LPS) is the most common histologic type [1-3] 
and is classified into 4 subtypes: well-differentiated (WD), 
dedifferentiated, myxoid/round cell (RC), and pleomor-
phic. Mixed-type LPS is rare and presents as two or more 
subtypes in a single tumor. Retroperitoneal liposarcoma 
(RPLS) is often asymptomatic and considerably large when 
initially diagnosed. Complete resection for curative intent 
is the treatment of choice, and a negative margin should 
be achieved to increase survival, even if resection of ad-
jacent organs is needed [4-8]. Despite complete resection, 
local recurrence is frequent and leads to mortality. 
However, other treatments (chemotherapy and radio-
therapy) have not been effective [2,9-13]. Besides the study 
of 21 Asians by Lee et al. [6], other RPLS studies have been 
based on Western populations. How RPLS in Asians com-
pares with RPLS in Western populations has not been 
studied. This paper is a study of the surgical treatment and 
prognosis of RPLS in a single Korean tertiary medical 
center.
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TABLE 1. Demographic details of patients and tumor 
characteristics at initial presentation
Total cases 
(n=19) 
Recurred cases 
(n=11) 
Age at initial diagnosis
Sex
    Male
    Female
Variant
    Well-differentiated
    Dedifferentiated
    Myxoid/round cell
    Pleomorphic
    Mixed type
Tumor burden
Margin
    Negative
    Positive
Adjacent organ resection
    Kidney
    Colon
    Small bowel
    Adrenal gland
    Othera
52.35 (31-72)
13 (68.4)
  6 (31.6)
  5 (26.3)
  2 (10.5)
  3 (15.8)
0 (0)
  9 (47.4)
52.3 (27-95)
17
2
11 (57.9)
6
3
3
3
4
48.25 (37-70)
7 (63.6)
4 (36.4)
3 (27.3)
2 (18.2)
2 (18.2)
0 (0)
4 (36.3)
51.1 (32-90)
9
2
5 (45.4)
2
3
3
3
1
Values are presented as mean (range) or number (%).
a: Other adjacent organs were omentum, spleen, and lung.
Additional treatment was provided for 8 patients, chemotherapy 
for 6 patients, and radiation therapy for 5 patients. Three pa-
tients died during the follow-up. Of these, two suffered from post-
operative morbidity. Local recurrence control failed in 1 patient 
and he was transferred to a secondary hospital for hospice care 
according to the patient’s will. One patient was under a do-not-re-
suscitate order owing to an underlying terminal supraglottic 
cancer. All other patients had no medical history other than es-
sential hypertension and fully recovered pulmonary tubercu-
losis. 
MATERIALS AND METHODS
Forty-eight patients with LPS were identified at our in-
stitute between July 1, 1984, and March 31, 2009. Fourteen 
patients not registered on the electronic medical record and 
14 patients with surgical sites other than the retro-
peritoneum (e.g., extremities, testis) were excluded. One 
patient who did not revisit the hospital was also excluded. 
Nineteen patients were included in the current study. The 
patients’ progression, outpatient records, operative notes, 
histopathological reports, and imaging studies were re-
viewed retrospectively. The study received Institutional 
Review Board and ethics committee approval.
RPLSs were classified into 5 histopathologic types ac-
cording to the World Health Organization classification: 
WD, dedifferentiated, myxoid/RC, pleomorphic, and mix-
ed-type [14].
The factors studied included age at diagnosis, sex, symp-
toms at presentation, histopathologic type, gross margin 
status, tumor size, tumor burden, disease recurrence after 
treatment, interval time from immediate previous surgery 
to disease recurrence, and treatment with chemotherapy 
or radiation therapy. In the immediate postoperative peri-
od, imaging studies (computed tomography [CT] or posi-
tron emission tomography) were conducted at 1 and 3 
months. If there was no evidence of recurrence for 1 year, 
imaging was done after 6 or 12 months. Tumor size was de-
fined as the maximum dimension on cross-sectional imag-
ing for a solitary mass and as the sum of all maximum di-
mensions for more than one mass. Tumor burden was de-
fined as the sum of 3 maximum tumor diameters. Morbidity 
and mortality analyses were conducted by reviewing 
charts and clinical records.
Statistics of survival and recurrence were analyzed by 
using the Kaplan-Meier method. The effect of prognostic 
factors on survival and recurrence was compared by using 
the log rank test. 
RESULTS
1. Patient evaluation and demographics
Nineteen RPLS patients were evaluated. All patients un-
derwent surgical treatment, and 35 total surgeries were 
done for curative purposes. The patient demographics are 
described in Table 1. The mean follow-up period was 66.8 
months (range, 6 to 165 months). 
2. Primary RPLS cases
Seventeen patients underwent their initial surgery at our 
hospital. The mixed subtype (52.9%) was the most common 
LPS, followed by WD (23.5%). Adjacent organ resection 
was performed in 10 patients (58.8%). The most commonly 
resected organs were the kidney and the adrenal glands 
(Table 2).
Four patients (cases 01 to 04) received adjuvant chemo-
therapy or radiation after the initial surgical treatment. Of 
these, case 01 was disease-free at 27 months and case 02 
at 48 months after therapy. Case 01 received radiation 
therapy only and case 02 received 2 cycles of chemotherapy 
followed by radiation therapy. Case 03 was treated with ad-
juvant radiation therapy and had recurrent disease 17 
years after the first operation. Reoperation was performed, 
and the patient has been disease-free for 4 months. Case 
04 underwent 6 cycles of chemotherapy and had recurrent 
disease at 29 months after the initial operation. Reopera-
tion was performed, followed by four additional cycles of 
chemotherapy. The patient suffered disease recurrence 
twice more, with each recurrence treated with surgical in-
tervention without chemotherapy. Radiation therapy was 
applied 1 month after the third reoperation, and no re-
currence was seen on an imaging study 1 month after radia-
tion therapy. No recurrence has been seen at 61 months 
since the initial diagnosis.
3. Recurrent RPLS cases
Recurrent disease was confirmed by imaging in 9 of 17 
patients. Among these 9 patients, cases 05 and 06 have 
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TABLE 2. Recurrence rates in patients who underwent their first 
operation in our hospital
Total cases 
(n=17)
Recurrence 
(n=9)
Interval 
from initial 
operation 
(mo)
Age at initial 
diagnosis
Sex
    Male
    Female
Variant
    Well-differentiated
    Dedifferentiated
    Myxoid/round cell
    Pleomorphic
    Mixeda
Margin
    Negative
    Positive
Adjacent organ 
resection
    Kidney
    Adrenal
    Colon
    Small bowel
    Otherb
49.4 (28-64)
11
6
4
2
2
0
9
15
2
11
6
5
3
3
4
49.9 (37-62)
   5 (45.5)
   4 (66.7)
   2 (50.0)
  2 (100)
   1 (50.0)
0 (0)
   4 (44.4)
   9 (75.0)
  2 (100)
   5 (45.5)
   2 (33.3)
   3 (60.0)
  3 (100)
  3 (100)
1 (25)
93.6
30.5
131.5
26.5
161.0
28.3
80.9
12.0
Values are presented as mean (range) or no. of recurred cases (%).
a: Mixed-type retroperitoneal liposarcoma was composed of 
well-differentiated (WD) and myxoid subtype in 5 patients, myx-
oid and pleomorphic in 2 patients, and WD and dedifferentiated 
in 2 patients, b: Other adjacent organs were omentum, spleen, and 
lung.
Seventeen patients underwent primary surgical treatment in our 
hospital. Of these, 8 patients were disease-free without re-
currence for a mean of 48.9 months, and 9 patients had recurrent 
disease during follow-up. Two patients were previously treated 
for liposarcoma before presenting to Yonsei University Severance 
hospital.
FIG. 1. Survival rate; The average survival was 223.8 months 
and the overall survival survival rate was 84.2%. The 5-year 
survival rate was 86.9%, and the 10-year survival rate was 
69.5%.
been disease-free for 50 and 296 months after 2 and 3 
rounds of reoperation, respectively. Case 07 underwent re-
operation 5 years after the first surgery, and recurrence 
was suspected at 7 years after the initial diagnosis. This 
patient is under close observation with imaging studies at 
3-month intervals, but no change has been seen for 1 year. 
As previously mentioned, cases 03 and 04 had recurrent 
disease after adjuvant chemotherapy or radiation therapy. 
Case 08 had disease recurrence twice (8 and 20 months af-
ter initial treatment) and underwent reoperation. Distant 
recurrence was seen on a CT image 1 month after the third 
operation, and adjuvant chemotherapy was initiated. 
After 8 cycles, partial response was achieved. A ninth cycle 
of chemotherapy was planned, but no further medical re-
cord exists.
4. Mortality and morbidity
A group of 3 patients (cases 09 to 11) had 2 cases of morbidity 
and 3 of mortality after surgical treatment. In case 09, in-
complete initial resection presented as the mixed-type his-
tology (myxoid/RC and pleomorphic), and adjuvant radia-
tion therapy was administered. Seven months after treat-
ment, disease recurrence was confirmed and 6 cycles of che-
motherapy were administered. Disease progression and 
newly developed distant metastasis were seen on a fol-
low-up CT scan, and the chemotherapy regimen was 
changed. After 1 cycle of the new regimen (15 months after 
the initial operation), the patient died of LPS progression. 
Case 10 underwent wide excision and adjacent organs 
(left kidney, pancreas, spleen, adrenal gland, transverse 
colon, and duodenum) were resected. However, complete 
resection was not possible. Wound dehiscence and in-
testinal obstruction were observed after the first operation, 
and surgical intervention was done for the intestinal 
obstruction. After 17 months the LPS recurred, but reoper-
ation was not possible due to the widely spread tumor and 
the patient’s poor general condition. The patient died 29 
months after the original diagnosis.
Case 11 initially underwent reoperation 3, 6, and 7 years 
after the initial treatment. During the fourth operation, 
complete resection was not possible. Bowel leakage devel-
oped and the patient died (8 years after the initial oper-
ation). Both of these latter cases were of the dediffer-
entiated subtype.
5. Survival, recurrence, and long-term survivors
Average survival was 223.8 (±38.2) months and the overall 
survival rate was 84.2%. The 3- and 5-year survival rates 
were 86.9%, and the 10-year survival rate was 69.5% (Fig. 
1).
Patients developed recurrence at a mean of 47.7 months. 
The mean time from initial surgery to first recurrence was 
93 months. Recurrence occurred at a mean of 13.1 months 
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FIG. 2. The interval of disease recurrence. RPLS, retroperitoneal 
liposarcoma.
TABLE 3. Recurrence interval from the immediately previous operation and imaging study
Operation Patients
Interval from the immediately-previous 
operation (mo)
Interval from the immediately-previous 
imaging study (mo)
Total
2nd 
3rd 
4th 
5th 
6th 
15
6
4
3
1
1
47.7 (3-237)
24.4 (3-60)a
     93 (29-237)
     40 (29-60)a
24.25 (12-40)
   8 (3-12)
  4
32
13.1 (1-80)
   7.9 (1-19)a
25.2 (3-80)
 11.5 (3-19)a
     6 (3-12)
     7 (3-11)
  1
11
Values are presented as mean (range).
a: Long-term recurrent patients were included. Two patients’ diseases recurred after 161 and 237 months.
after a previous imaging study (Table 3). The recurrence 
interval was significantly shorter in recurrent RPLS cases 
than in primary cases (p=0.023) (Fig. 2). 
Recurrence of histopathologic subtypes was 60% for WD, 
100% for dedifferentiated, 66% for myxoid/RC, and 44.4% 
for mixed-type RPLS. Among sex, age, histopathologic sub-
type, tumor size or burden, and resection of adjacent or-
gans, there were no significant prognostic factors for re-
currence or survival.
In several cases the recurred histopathologic diagnosis 
differed from the primary subtype. Cases 04 and 12, whose 
initial histopathologic subtype was WD, experienced re-
currence of the dedifferentiated subtype. In case 06, the ini-
tial histopathology showed WD, but on recurrence the myx-
oid subtype was diagnosed after the first reoperation and 
the dedifferentiated subtype after the second reoperation.
Survival for more than 3 and 5 years was observed in 12 
and 8 patients, respectively. Among these long-term survi-
vors, 5 patients were reported to have mixed-type histo-
pathology: WD and myxoid presented together in 4 pa-
tients (cases 05, 07, 13, 14) and myxoid and pleomorphic 
presented together in case 15. The histopathologic subtype 
of case 11 was the dedifferentiated type in all 4 surgeries. 
Case 04 was initially diagnosed as WD but subsequent his-
topathological reports after three reoperations showed de-
differentiated, mixed (WD and dedifferentiated), and WD, 
respectively. Case 06 underwent three surgeries, with each 
histopathologic result showing WD, myxoid, and dediffer-
entiated LPS.
DISCUSSION
RPLS is a rare disease and has a significantly better prog-
nosis than other soft tissue sarcomas (leiomyosarcoma, 
malignant fibrous histiocytoma, malignant peripheral 
nerve sheath tumor, and hemangiosarcoma). Histological 
grade, resection margin, and tumor invasion of adjacent 
structures are known to affect RPS prognosis [1,3,15-19]. 
A study of 177 patients with primary RPLS operated on 
for curative intent by Singer et al. [4] reported disease-free 
survival rates of 73% at 3 years and 60% at 5 years. 
Histologic subtype, incomplete resection, and contiguous 
organ resection were associated with survival. When RPLS 
recurred locally, recurrence size, primary histologic var-
iant and grade, and recurrence growth rate were in-
dependent predictors of disease-specific survival. For pa-
tients undergoing reoperation on locally recurrent RPLS, 
recurrence size and recurrence growth rate independently 
influenced the development of a second local recurrence, 
and repeated resection improved survival only for tumors 
with a growth rate of less than 0.9 cm/mo [20]. Of the pa-
tients studied, 56% presented with WD, 37% with dediffer-
entiated, 5% with myxoid, and 2% with RC RPLS. The de-
differentiated type was associated with a 6-fold increased 
risk of death compared with the WD type. Important prog-
nostic factors for survival were incomplete resection, con-
tiguous organ resection, and age ＞63 years. Nephrectomy 
was not associated with disease-specific survival; there-
fore, the authors proposed that kidney parenchymal spar-
ing can be performed without influencing disease-specific 
survival [4]. 
Neuhaus et al. [5] reported a study of 72 patients who un-
derwent surgical treatment for primary RPLS. More than 
half had excision of a continuous organ to achieve clea-
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rance. Direct tumor infiltration was seen in only 4% of 
patients. This supports the proposal by Singer et al. [4] of 
kidney sparing when possible. In this study, the authors 
did not see recurrence itself as an indication for further sur-
gical treatment, and only surgery for palliative treatment 
was supported. 
However, a study by Milone et al. [7] on 21 RPLS patients 
encouraged prompt surgical treatment for local recur-
rence. In that study, patients who had undergone complete 
resection of recurrent disease had a better mean survival 
than did patients who had not undergone complete 
resection. Therefore, a shorter follow-up interval was sug-
gested for improved survival. Shibata et al. [21] also pro-
posed that incomplete surgical resection, providing in-
creased survival and symptom palliation, can be beneficial 
for selected patients with unresectable RPLS [1].
Although RPS is known to infiltrate the surrounding vis-
cera, studies on RPLS have reported that direct organ in-
filtration is rare, suggesting a “pushing” character [5]. 
However, a recent study by Mussi et al. [19] reported that 
LPS involved 62.3% of resected viscera and that even WD, 
which is known to be least infiltrative, involved 48.6% of 
resected viscera. This may be why contiguous organ re-
section during surgery is negatively associated with local 
and distant recurrence and disease-free survival [4]. In our 
study, contiguous organ resection was not significantly as-
sociated with decreased recurrence. This was probably due 
to our limited sample size. 
Treatment modalities other than surgical intervention 
such as chemotherapy and radiation therapy have not yet 
been established. Chemotherapy on LPS originating from 
the lower or upper extremities has been shown to be 
beneficial. The myxoid subtype is more chemosensitive, 
and ifosfamide has been shown to be more effective than 
doxorubicin [12,13]. No studies showing the effectiveness 
of chemotherapy on RPLS have been reported. Although 
some studies have reported that radiation therapy is bene-
ficial for RPS, its effect on survival is still under debate. 
Morbidities due to toxicity on adjacent radiosensitive cen-
tral organs remain an important obstacle [2,10,11,22-28]. 
Nearly all studies on RPLS have been based on Western 
populations. A recent report by Lee et al. [6] was conducted 
on 21 Asian patients. In these patients, 61.9% of the tumors 
were WD, 19% were myxoid/RC, 14.3% were dediffer-
entiated, and 4.8% had pleomorphic morphology. Surgical 
margins were involved in 10 (47.6%) patients. Resection of 
contiguous organs was required in 15 (71.4%) to achieve 
gross surgical margins. Eleven of 21 (52%) patients had tu-
mor recurrence. Median disease-free survival was 19 
months and the overall 3- and 5-year survival rates were 
87% and 49%, respectively.
Our study based on a Korean population from a single 
tertiary medical center evaluated 19 patients who under-
went RPLS treatment. Histopathologic subtypes included 
26.3% WD, 10.5% dedifferentiated, and 15.8% myxoid/RC. 
The remaining 47.4% were mixed-type, accounting for a 
considerably high proportion of cases. Two cases were com-
posed of WD and dedifferentiated. This may reflect the pop-
ular theory that dedifferentiated LPS is a transition from 
WD LPS to a nonlipogenic sarcoma [29,30]. Even without 
these two cases, 36.8% were “true” mixed-type RPLS. 
Mixed-type RPLS is a rare subtype [31,32]. There were no 
reports of mixed-type RPLS in the other studies we re-
viewed [4-6]. De Vreeze et al. [33] recently reported a radio-
logical, histopathological, and molecular biological analy-
sis of mixed-type LPS. In that study, 9 patients with low-
er-extremity LPS presented with a mixed morphology (WD 
and myxoid). However, immunohistochemical analysis of 
MDM2 and CDK4 confirmed 4 patients with WD and 5 pa-
tients with myxoid. 
In our study, the overall survival rate was 84.2% (16 of 
19 patients) during a mean follow-up of 66.8 months. The 
3- and 5-year survival rates were 86.9%, and the 10-year 
survival rate was 69.5%. This is comparable to previous 
RPLS studies reporting an overall survival rate of 52 to 74% 
during a mean follow-up of 26 to 60 months [4,5,7]. Singer 
et al. [4] reported 3- and 5-year survival rates of 73% and 
60%, respectively, and Milone et al. [7] reported a 5-year 
survival rate of 85.7% when complete resection was 
achieved.
In our study, recurrence after initial surgery occurred in 
9 of 17 patients (52.9%) after a mean of 93 months. The dis-
ease-free rate of primary RPLS at 3 and 5 years was 66.1% 
and 47.0%, respectively. The overall mean interval be-
tween operations was 47.7 months. This was similar to pre-
vious reports of recurrence rates of 41.4 to 55.6% with a dis-
ease-free period of 20 to 45 months [4,5,7]. Singer et al. [4] 
reported a disease-free rate of 52% and 41%, respectively, 
at the 3- and 5-year follow-ups.
According to the study of Singer et al. [4], local recurrence 
size and local recurrence growth rate independently influ-
ence the development of a second local recurrence. They 
proposed a “one centimeter per month rule”: RPLS with a 
growth rate lower than 0.9 cm per month on the first re-
currence presents with a better disease-specific survival 
and is associated with improved survival after aggressive 
resection of the local recurrence [20]. In our study, the mean 
growth rate of tumors on the first recurrence was 0.34 cm 
per month. All but one patient had a growth rate less than 
0.9 cm per month. This may explain the relatively high sur-
vival rate of our study. However, local recurrence size was 
not a significant prognostic factor for locally recurred 
RPLS.
Our survival and recurrence rates were higher than 
those previously reported for Asians by Lee et al. [6]. Their 
lower survival rate probably owes to the high margin-pos-
itive rate of 47.6%, despite an aggressive surgical approach 
with a contiguous organ resection rate of 71.4%. The re-
currence interval had a tendency to shorten as the disease 
recurred again, from 93 months on first recurrence to 24.3 
and 8 months on the second and third recurrences, 
respectively. The recurrence interval was significantly 
shorter in recurrent RPLS cases than in primary cases. 
This finding is consistent with the report by Neuhaus et al. 
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[5].
An interesting fact in our study was the high proportion 
of mixed-type LPS. The long-term survivors of our study 
(50%), even with the WD/dedifferentiated variant ex-
cluded, presented with various subtypes. In some cases, 
the primary and recurrent RPLS of the same patient 
showed different histopathologic subtypes. Mixed-type 
LPS is a rare entity that has yet to be fully illuminated. 
CONCLUSIONS
RPLS is the most common histologic type of retroperitoneal 
malignant tumors. Many studies have been published on 
RPLS, and complete resection is the gold standard of treat-
ment, leading to increased survival rates and lower re-
currence rates. Even in unresectable cases, partial re-
section may be beneficial. Whether chemotherapy or radia-
tion therapy is effective is still under debate. Even after 
complete resection, disease recurrence is common and thus 
repeated resection is recommended.
Our study reported higher survival rates than reported 
by other groups. The low tumor growth rate of recurrent 
RPLS in this study may be attributed to such results. 
Recurrence rates were higher and the recurrence interval 
was shorter in recurrent RPLS.
Another interesting result of our study was the high 
prevalence of the mixed type of RPLS. The cause of this high 
prevalence and whether it is associated with better prog-
nosis is not known and requires further research. 
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